Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer

The investigational oral DNA vaccine VXM01 targets the vascular endothelial growth factor receptor 2 (VEGFR-2) and uses Salmonella typhi Ty21a as a vector. The immune reaction elicited by VXM01 is expected to disrupt the tumor neovasculature and, consequently, inhibit tumor growth. VXM01 potentially...

Full description

Bibliographic Details

Main Authors:	Niethammer, Andreas Gerhard (Author) , Mikus, Gerd (Author) , Knebel, Phillip (Author) , Hohmann, Nicolas (Author) , Leowardi-Bauer, Christine (Author) , Beckhove, Philipp (Author) , Akhisaroglu, Mustafa (Author) , Ge, Yingzi (Author) , Grenacher, Lars (Author) , Büchler, Markus W. (Author) , Koch, Moritz (Author) , Weitz, Jürgen (Author) , Haefeli, Walter E. (Author) , Schmitz-Winnenthal, Friedrich Hubertus (Author)
Format:	Article (Journal)
Language:	English
Published:	20 August 2012
In:	BMC cancer Year: 2012, Volume: 12
ISSN:	1471-2407
DOI:	10.1186/1471-2407-12-361
Online Access:	Resolving-System, kostenfrei, Volltext: http://dx.doi.org/10.1186/1471-2407-12-361 Verlag, kostenfrei, Volltext: https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-361
Author Notes:	Andreas G. Niethammer, Heinz Lubenau, Gerd Mikus, Philipp Knebel, Nicolas Hohmann, Christine Leowardi, Philipp Beckhove, Mustafa Akhisaroglu, Yingzi Ge, Marco Springer, Lars Grenacher, Markus W. Buchler, Moritz Koch, Jürgen Weitz, Walter E. Haefeli and Friedrich H. Schmitz-Winnenthal